Back to News
Market Impact: 0.2
Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day
Source: GlobeNewswire
Healthcare & BiotechCompany Fundamentals
Licaminlimab’s genotype-based precision-medicine approach for TNFR1-mediated dry eye disease remains on track for a topline readout around year-end in the PREDICT-1 registrational symptoms trial. The headline reports no trial results or other numerical data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- Former world No. 1 Jon Rahm's lawyer tells court Spaniard is done with LIV Golf after three seasons
- Anthropic will be 'most ridiculous IPO' of year, analyst says
- Levi Strauss hikes profit guidance after tariff refunds, but its sales outlook is less optimistic
- Samsung Q3 profit surges to record high, but misses lofty expectations
- Brazil is having its Argentina moment. How to play it
- Streamex CIO Mitchell Williams sells $35,239 in company stock